Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options
If users saw no change in the first 14 days, they routinely bumped up their dose, switched injection sites, or questioned if their peptide was real
They should not be interpreted as claims regarding approved medical use
Name: BPC 157 Alias: Booly Protection Compound 15, Pentadecapeptide, BPC 157 CAS: 137525-51-0 Sequence: Gly-Glu-Pro-Pro-Pro-Gly- Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val MF: C62H98N16O22 MW: 1419.53552 Purity: 99% Appearance: White Lyophilized Powder Standard: USP Certification: SGS Method of Analysis: HPLC Storage: Lyophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18 C
Semaglutide and tirzepatide are GLP-1 receptor agonists
